Want to see CUE full AI Analyst Report?
Top Page
Cue Biopharma
(NASDAQ:CUE)
Select Model
Select Model
Rating:48Neutral
Price Target:
$27.00
▼(-15.94% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily held back by weak financial performance—large losses and persistent cash burn despite improving revenue and strong gross margins. Technicals also point to a soft near-term trend (below key moving averages with negative MACD). Offsetting these, recent corporate actions—particularly the $50M private placement and leadership upgrades—support liquidity and execution capacity, modestly lifting the overall assessment.
Positive Factors
Revenue Growth & Margins
Sustained revenue growth (+19.2% TTM) combined with very high gross margins (~72.6%) indicates the company records revenue with favorable unit economics. Over months this supports more efficient use of R&D spend, an ability to scale collaborative revenue, and a clearer path to narrowing operating losses if growth persists.
Negative Factors
Cash Burn
Persistent negative operating and free cash flow (~ -$24.6M TTM) signals ongoing funding requirements to sustain operations. Absent accelerating revenue or repeat non-dilutive funding, continued burn increases reliance on financings, raising dilution risk and potentially constraining progress on costly clinical trials over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Margins
Sustained revenue growth (+19.2% TTM) combined with very high gross margins (~72.6%) indicates the company records revenue with favorable unit economics. Over months this supports more efficient use of R&D spend, an ability to scale collaborative revenue, and a clearer path to narrowing operating losses if growth persists.
Read all positive factors
Cue Biopharma (CUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$233.46M
Dividend YieldN/A
Average Volume (3M)121.76K
Price to Earnings (P/E)―
Beta (1Y)2.84
Revenue Growth354.37%
EPS Growth-63.33%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,826,387
10 Day Avg. Volume146,729
30 Day Avg. Volume121,763
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.09
Price to Sales (P/S)1.05
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cue Biopharma Business Overview & Revenue Model
Company Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various...
How the Company Makes Money
Cue Biopharma does not have publicly established, recurring product sales from approved therapies; its revenue has primarily been generated through collaboration-related arrangements and other sources typical of clinical-stage biotech companies. K...
Cue Biopharma Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.65M | 27.47M | 9.29M | 5.49M | 1.25M | 14.94M |
| Gross Profit | 37.54M | 27.47M | 9.29M | -32.61M | 1.25M | 16.72M |
| EBITDA | -95.89M | -22.27M | -37.53M | -46.05M | -50.49M | -45.44M |
| Net Income | -164.11M | -26.60M | -40.67M | -50.73M | -53.01M | -44.16M |
Balance Sheet | ||||||
| Total Assets | 30.71M | 42.21M | 32.19M | 61.53M | 91.28M | 83.40M |
| Cash, Cash Equivalents and Short-Term Investments | 17.39M | 27.14M | 23.39M | 48.51M | 76.29M | 64.37M |
| Total Debt | 3.08M | 4.20M | 8.88M | 14.70M | 19.32M | 12.02M |
| Total Liabilities | 28.40M | 15.78M | 14.69M | 24.45M | 25.60M | 17.91M |
| Stockholders Equity | 2.31M | 26.43M | 17.50M | 37.09M | 65.68M | 65.49M |
Cash Flow | ||||||
| Free Cash Flow | -50.17M | -21.86M | -36.40M | -39.96M | -41.98M | -39.75M |
| Operating Cash Flow | -50.05M | -21.69M | -36.33M | -39.96M | -41.81M | -38.84M |
| Investing Cash Flow | 131.00K | 75.00K | 32.00K | 25.00M | -24.61M | 9.11M |
| Financing Cash Flow | 39.82M | 26.29M | 10.24M | 11.86M | 53.66M | 19.23M |
Cue Biopharma Technical Analysis
Positive
32.12
Price Trends
29.53
Positive
24.23
Positive
18.37
Positive
Market Momentum
0.15
Negative
61.86
Neutral
89.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Positive. The current price of 32.12 is above the 20-day moving average (MA) of 29.81, above the 50-day MA of 29.53, and above the 200-day MA of 18.37, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 61.86 is Neutral, neither overbought nor oversold. The STOCH value of 89.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CUE.
Cue Biopharma Risk Analysis
Cue Biopharma disclosed 66 risk factors in its most recent earnings report. Cue Biopharma reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cue Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $233.46M | -1.27 | -1032.19% | ― | 354.37% | -63.33% | |
44 Neutral | $43.03M | -0.94 | -160.72% | ― | 893.01% | 41.74% | |
44 Neutral | $85.16M | -2.21 | -284.80% | ― | ― | -7.28% | |
42 Neutral | $20.14M | -0.19 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $83.56M | -1.04 | -70.14% | ― | ― | 16.04% |
* Healthcare Sector Average
CUE
Cue Biopharma
34.20
9.64
39.23%
CELU
Celularity
0.70
-3.46
-83.25%
ALGS
Aligos Therapeutics
6.89
-1.88
-21.44%
GNTA
Genenta Science SpA Sponsored ADR
1.30
-2.28
-63.69%
MAIA
MAIA Biotechnology, Inc.
1.40
-0.18
-11.39%
ACRV
Acrivon Therapeutics, Inc.
1.95
0.56
40.29%
Cue Biopharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cue Biopharma Appoints Veteran James Ahlers as CFO
Positive
Aug 3, 2026
Cue Biopharma, Inc. announced on August 3, 2026, that its board appointed veteran life sciences finance executive James Ahlers as chief financial officer and principal financial officer, effective July 30, 2026, underscoring the company’s fo...
Business Operations and StrategyPrivate Placements and Financing
Cue Biopharma Announces $50 Million Private Placement
Positive
Jul 10, 2026
On July 9, 2026, Cue Biopharma entered into a securities purchase agreement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to raise approximately $50 million through a private placement of co...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Cue Biopharma Shareholders Approve 2026 Stock Incentive Plan
Positive
Jun 3, 2026
At a special meeting of stockholders held on June 1, 2026, Cue Biopharma shareholders approved the company’s 2026 Stock Incentive Plan, formalizing a new equity-based compensation framework previously adopted by the board. The plan’s a...
Business Operations and StrategyExecutive/Board Changes
Cue Biopharma Streamlines Governance and Strengthens Leadership Team
Positive
Jun 2, 2026
On May 29, 2026, Cue Biopharma announced that directors Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen resigned from its board and board committees by mutual agreement, with the company emphasizing there were no disagreements rela...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.